Arch Therapeutics, Inc.
ARTHOTCHealthcare
$0.00
+$0.00(+0.00%)
Market Cap$444
P/E Ratio—
52W High$1.567
52W Low$0.0001
Arch Therapeutics, Inc. (ARTH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ARTH · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2024Report Date: Aug 19, 2024EPS Actual
-$1.44
Est. $70.00 · -102.1%
Revenue
$0.00B
Est. $0.11B · -100.0%
Fiscal Period
Q3 FY2024
FY ends December
Report Date
Aug 19, 2024
After Market Close
▼ Miss EPS▼ Miss Revenue
ARTH reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.01
Rev. $0.48B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.01
Rev. Est.$0.48B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2025 | Aug 18, 2025 | — | — | — | — | — | — |
| ◌ Q2 FY2025 | Apr 29, 2025 | — | — | — | — | — | — |
| ◌ Q1 FY2025 | Mar 28, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Dec 27, 2024 | — | — | — | — | — | — |
| ▼ Q3 FY2024 | Aug 19, 2024 | $70.00 | -$1.44 | -102.1% | $0.00B | $0.11B | -100.0% |
| ▼ Q2 FY2024 | May 9, 2024 | $74.00 | -$0.33 | -100.5% | $0.00B | $0.11B | -100.0% |
| ▼ Q1 FY2024 | Feb 15, 2024 | -$0.13 | -$0.80 | -515.4% | $0.00B | $0.00B | -96.7% |
| ▼ Q4 FY2023 | Dec 29, 2023 | -$0.13 | -$0.52 | -303.1% | $0.00B | $0.00B | -97.2% |
Q3 FY2025
Aug 18, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
Apr 29, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 28, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Dec 27, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 19, 2024Miss
EPS Actual
-$1.44
EPS Est.
$70.00
EPS Surpr.
-102.1%
Revenue
$0.00B
Q2 FY2024
May 9, 2024Miss
EPS Actual
-$0.33
EPS Est.
$74.00
EPS Surpr.
-100.5%
Revenue
$0.00B
Q1 FY2024
Feb 15, 2024Miss
EPS Actual
-$0.80
EPS Est.
-$0.13
EPS Surpr.
-515.4%
Revenue
$0.00B
Q4 FY2023
Dec 29, 2023Miss
EPS Actual
-$0.52
EPS Est.
-$0.13
EPS Surpr.
-303.1%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $82.00 | $82.00 | $82.00 | 1 |
| Q2 FY2024 | $70.00 | $70.00 | $70.00 | 1 |
| Q1 FY2024 | $74.00 | $74.00 | $74.00 | 1 |
| Q4 FY2023 | $68.00 | $68.00 | $68.00 | 1 |
| Q3 FY2023 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q2 FY2023 | $2.00 | $2.00 | $2.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2024 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2024 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2023 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2024 | Aug 19, 2024 | -102.1% | $0.67 | $0.67 | +0.00% |
| ▼ Q2 FY2024 | May 9, 2024 | -100.5% | $0.95 | $1.04 | +9.47% |
| ▼ Q1 FY2024 | Feb 15, 2024 | -515.4% | $3.00 | $3.00 | +0.00% |
| ▼ Q4 FY2023 | Dec 29, 2023 | -303.1% | $6.80 | $7.24 | +6.47% |
| ▼ Q3 FY2023 | Aug 11, 2023 | -171.0% | $1.54 | $1.55 | +0.65% |
| ▼ Q2 FY2023 | May 23, 2023 | -89.5% | $2.90 | $3.00 | +3.45% |
| ▼ Q1 FY2023 | Feb 14, 2023 | -172.0% | $3.30 | $3.25 | -1.52% |
| ▲ Q4 FY2022 | Dec 28, 2022 | +0.0% | $6.40 | $5.90 | -7.81% |
Q3 FY2024+0.00%
Report Date
Aug 19, 2024
EPS Beat/Miss
-102.1%
Price Before
$0.67
Price After
$0.67
Q2 FY2024+9.47%
Report Date
May 9, 2024
EPS Beat/Miss
-100.5%
Price Before
$0.95
Price After
$1.04
Q1 FY2024+0.00%
Report Date
Feb 15, 2024
EPS Beat/Miss
-515.4%
Price Before
$3.00
Price After
$3.00
Q4 FY2023+6.47%
Report Date
Dec 29, 2023
EPS Beat/Miss
-303.1%
Price Before
$6.80
Price After
$7.24
Q3 FY2023+0.65%
Report Date
Aug 11, 2023
EPS Beat/Miss
-171.0%
Price Before
$1.54
Price After
$1.55
Q2 FY2023+3.45%
Report Date
May 23, 2023
EPS Beat/Miss
-89.5%
Price Before
$2.90
Price After
$3.00
Q1 FY2023-1.52%
Report Date
Feb 14, 2023
EPS Beat/Miss
-172.0%
Price Before
$3.30
Price After
$3.25
Q4 FY2022-7.81%
Report Date
Dec 28, 2022
EPS Beat/Miss
+0.0%
Price Before
$6.40
Price After
$5.90
Avg Beat Reaction-7.81%
Avg Miss Reaction+2.65%
Beat Rate1 / 8 quarters
Largest Move+9.47% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ARTH ends December
Arch Therapeutics, Inc. (ARTH) most recently reported earnings on August 19, 2024 for Q3 FY2024, posting EPS of $-1.44 — missing the analyst consensus of $70.00 by -102.1%. The next ARTH earnings date is expected around September 1, 2026.
Each quarter, investors track ARTH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ARTH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ARTH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ARTH earnings · 5 questionsArch Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ARTH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ARTH historically reports after market close (AMC).
ARTH earnings datewhen is ARTH earningsARTH next earnings datewhen does ARTH report earningsARTH earnings calendar
▸ Source: FMP · Arch Therapeutics, Inc. SEC filings · US GAAP · Arch Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026